FROM MOLECULES TO TREATMENTS: BUSINESS MODELS FOR NEW DRUG DISCOVERY.

The modern-age drug discovery is a long and complex process that relies on multiple scientific disciplines and technologies, among which the use of multiple high-resolution structural biology methods. It also relies on strong partnerships between the various stakeholders - academia, pharmaceutical industry, SMEs, regulators, patients...
EATRIS, the European Research Infrastructure for Translational Medicine, and Biocat, the cluster organisation of life sciences and healthcare innovation in Catalonia, join forces to propose this forum within the frame of iNext-Discovery, an H2020 project enabling access to structural biology research infrastructures for all European researchers, with a triple objective:

To make drug discovery scientists, including structural biologists, more familiar with the full drug-development process and the partnership opportunities it can offer, both in academia and industry.
To stimulate the wider uptake of early drug discovery methods and structural biology across scientific disciplines and research sectors.
To foster collaboration between the different drug discovery stakeholders.

This event is designed for:

Biomedical Researchers with interest and/or first experience in working with industry.
Scientific Infrastructures, platforms and research centres (e.g. target providers, biobanks, libraries of compounds) that participate in early drug development and want to understand the commercialisation and partnering landscape.
Entrepreneurs and researchers aiming to develop a business activity (e.g. start-up, spin-off, licence, co-development).
Corporates that want to learn about challenges and ideas in academia.
Research Institutes linked to hospitals providing or requiring scientific underpinning for new drug Discovery.

Registration is free of charge and open from 2 April to 7 June 2024.

To register click on the following link.

For more information visit the web.